Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2716 to 2730 of 9102 results

  1. Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]

    In development Reference number: GID-TA11572 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Islatravir–lenacapavir for treating HIV-1 in people with virological suppression on standard HIV-1 treatment [TSID12428]

    Awaiting development Reference number: GID-TA12475 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Iberdomide with dexamethasone and daratumumab for treating relapsed or refractory multiple myeloma after 1 or 2 lines of treatment [TSID12415]

    Awaiting development Reference number: GID-TA12466 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 6 July 2026.

    In consultation

  5. Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment

    In development Reference number: GID-HTG10868 Expected publication date:  15 September 2026

    HealthTech guidance
    In development

  6. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]: final draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 9 July 2026.

    Technology appraisal guidance
    In consultation

  9. Povorcitinib for treating non-segmental vitiligo [GID-TA12019]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Povorcitinib for treating prurigo nodularis [GID-TA12018]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 31 July 2026.

    Technology appraisal guidance
    In consultation

  12. Self-directed automated audiometry for the diagnosis of hearing loss in adults (provisional title)

    In development Reference number: GID-HTG10909 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Bladder cancer: diagnosis and management (update): scoping

    We are listening to your views on this NICE guideline. Comments close 6 August 2026.

    NICE guideline
    In consultation

  14. Catumaxomab for intraperitoneal treatment of malignant ascites caused by EpCAM-positive carcinomas when further systemic anticancer treatment is unsuitable [ID6580]

    In development Reference number: GID-TA11774 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Bladder cancer: diagnosis and management (update)

    In development Reference number: GID-NG10452 Expected publication date: TBC

    NICE guideline
    In development